DashboardPortfoliosWatchlistCommunityDiscoverScreener
  • Community
  • /
  • Canada
  • /
  • Pharmaceuticals & Biotech
Author Program NEWCreate Narrative
CURA logo

Curaleaf Holdings, Inc. Stock Price

TSX:CURA Community·CA$3.8b Market Cap
  • 3 Narratives written by author
  • 0 Comments on narratives written by author
  • 31 Fair Values set on narratives written by author
Author Program NEWCreate Narrative

CURA Share Price Performance

CA$14.66
3.92 (36.50%)
​
CA$18.54
Fair Value
CA$14.66
3.92 (36.50%)
20.9% undervalued intrinsic discount
CA$18.54
Fair Value
Price CA$14.66
AnalystConsensusTarget CA$18.54
AnalystHighTarget CA$21.02
AnalystLowTarget CA$16.17
Thu, 3 Sep 26
Fair ValueCA$18.54
Share Pricen/a

CURA Community Narratives

AN
AnalystConsensusTarget
AnalystConsensusTarget's
Fair Value
·
Fair Value CA$18.54 20.9% undervalued intrinsic discount

Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities

1users have liked this narrative
0users have commented on this narrative
17users have followed this narrative
AN
AnalystHighTarget
AnalystHighTarget's
Fair Value
·
Fair Value CA$21.02 30.2% undervalued intrinsic discount

Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities

0users have liked this narrative
0users have commented on this narrative
1users have followed this narrative
AN
AnalystLowTarget
AnalystLowTarget's
Fair Value
·
Fair Value CA$16.17 9.4% undervalued intrinsic discount

Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes

0users have liked this narrative
0users have commented on this narrative
0users have followed this narrative
CURA logo
Curaleaf Holdings
20.9% undervalued intrinsic discount

Regulatory Winds Will Drive New Industry Leadership And Outperformance Opportunities

View narrative
AN
AnalystConsensusTarget
AnalystConsensusTarget
Updated 3 Sep
Read Narrative
CURA logo
Curaleaf Holdings
30.2% undervalued intrinsic discount

Medical Cannabis Legalization And Wellness Trends Will Redefine Market Opportunities

View narrative
AN
AnalystHighTarget
AnalystHighTarget
Updated 20 Aug
Read Narrative
CURA logo
Curaleaf Holdings
9.4% undervalued intrinsic discount

Intensified Global Regulation Will Squeeze Cannabis Margins Despite European Hopes

View narrative
AN
AnalystLowTarget
AnalystLowTarget
Updated 8 Jul
Read Narrative

Trending Discussion

No trending discussion available.

Recently Updated Narratives

AN
AnalystConsensusTarget
CURA logo

CURA: Hostile Aurora Bid And Reverse Split Will Support Future Earnings Power

Fair Value: CA$18.54 20.9% undervalued intrinsic discount
17 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystHighTarget
CURA logo

CURA: Hostile Aurora Bid And Q2 Execution Will Drive Future Upside

Fair Value: CA$21.02 30.2% undervalued intrinsic discount
1 fair value setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative
AN
AnalystLowTarget
CURA logo

CURA: Retail Expansion And Capital Actions Will Support Future Re Rating

Fair Value: CA$16.17 9.4% undervalued intrinsic discount
0 fair values setusers have set this as their fair value
0 commentsusers have commented on this narrative
0 likesusers have liked this narrative

Snowflake Analysis

Undervalued with mediocre balance sheet.

3 Risks
4 Rewards
View Full Analysis

Curaleaf Holdings, Inc. Key Details

US$1.3b

Revenue

US$665.7m

Cost of Revenue

US$649.6m

Gross Profit

US$690.8m

Other Expenses

-US$41.2m

Earnings

Last Reported Earnings
Jun 30, 2026
Next Reporting Earnings
n/a
-0.16
49.39%
-3.13%
94.2%
View Full Analysis

About CURA

Founded
n/a
Employees
5554
CEO
Boris Jordan
WebsiteView website
www.curaleaf.com

Curaleaf Holdings, Inc. engages in the retail and wholesale of cannabis products in the United States and internationally. The company operates licensed cultivation; and pharma-grade cannabis processing and manufacturing facilities. It also supplies cannabis on a wholesale basis to Australia, New Zealand, the United Kingdom and various European countries, including Germany, Italy, Poland, the Czech Republic, Switzerland, Sweden and Norway. In addition, the company operates a medical cannabis clinic and holds a pharmacy license. It serves the medical and adult-use cannabis markets through retail and wholesale channels. The company is based in Stamford, Connecticut.

Recent CURA News & Updates

User avatar
Narrative Update • Sep 03

CURA: Hostile Aurora Bid And Reverse Split Will Support Future Earnings Power

Curaleaf Holdings' analyst price targets have shifted higher into a CA$20 to CA$21 range, with analysts pointing to updated expectations for revenue growth, profit margins and valuation multiples as key drivers of the change. Analyst Commentary Recent Street research on Curaleaf Holdings highlights how analysts are recalibrating their views after the Q2 report and the 1 for 3 reverse stock split in June.

Recent updates

No updates

Curaleaf Holdings, Inc. Competitors

APTX logo

Apotex Health

Symbol: TSX:APTX
Market cap: CA$7.8b
GTII logo

Green Thumb Industries

Symbol: CNSX:GTII
Market cap: CA$2.2b
CRON logo

Cronos Group

Symbol: TSX:CRON
Market cap: CA$1.7b
View more competitors

Make Better Investing Decisions Anywhere

Scan to download
Open AppStoreOpen Google Play
Chrome Web Store
Level 5, 320 Pitt Street, Sydney
Financial Data provided by S&P Global Market Intelligence LLC, analysis provided by Simply Wall Street Pty Ltd. Copyright © 2026, S&P Global Market Intelligence LLC. All rights reserved.
View Data Sources
Markets
  • US: NYSE & NASDAQ
  • UK: FTSE
  • Australia: ASX
  • India: NIFTY
  • Canada: TSX
  • South Africa: JSE
  • Japan: NIKKEI
  • South Korea: KOSPI
  • Germany: DAX
Investing Ideas
  • Undervalued Companies
  • Dividend Powerhouses
  • Insider Buying
  • Nuclear Energy
  • Autonomous Vehicles
  • Artificial Intelligence
  • Crypto and Blockchain
  • Cybersecurity
  • More ideas
Stock Communities
  • AstraZeneca
  • HSBC Holdings
  • Shell
  • Unilever
  • Diageo
  • Rio Tinto Group
  • RELX
  • BP
  • Barclays
Features & Tools
  • Portfolio Tracker
  • Stock Screener & Alerts
  • Narratives & Fair Values
  • Dividend Calculator
News & Discovery
  • Latest Stock News
  • Global Market Insights
  • The Foxhole
  • Investing Ideas
  • Community Narratives
  • What's New
Simply Wall St
  • Plans & Pricing
  • Advertising
  • About Us
  • Contact Us
  • Careers
  • Help Center
  • Learn Stock Investing
  • Affiliate Program
  • Business & Enterprise
  • Charlie AI
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.
© 2026 Simply Wall Street Pty Ltd, US Design Patent #29/544/281, Community and European Design Registration #2845206
  • Terms and Conditions
  • Privacy Policy
  • AI Terms
  • Financial Services Guide